Nadia Khalil

Dr. Nadia Khalil


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SBS. Botros
S. Botros
NKNadia Khalil
Nadia Khalil
BNBassem H. Naguib
Bassem H. Naguib
YEYara El-Dash
Yara El-Dash

1 April 2014 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
NKNadia Khalil
Nadia Khalil
EAEman Mohamed Ahmed
Eman Mohamed Ahmed
KMKhaled Omar Mohamed
Khaled Omar Mohamed
YNYassin Nissan
Yassin Nissan
SZSawsan Zaitone
Sawsan Zaitone

1 October 2011 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
ATAzza Taher
Azza Taher
NKNadia Khalil
Nadia Khalil
EAEman M. Ahmed
Eman M. Ahmed

21 December 2012 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
MSMakarem M. Saeed
Makarem M. Saeed
NKNadia Khalil
Nadia Khalil
EAEman Ahmed
Eman Ahmed
KEKholoud I. Eissa
Kholoud I. Eissa

27 May 2009 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
KAKhaled A. M. Abouzid
Khaled A. M. Abouzid
NKNadia Khalil
Nadia Khalil
EAEman M. Ahmed
Eman M. Ahmed
HEHekmat A. Abd El-Latif
Hekmat A. Abd El-Latif
MEMoustafa El-Araby
Moustafa El-Araby

1 January 2015 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Closed access
NKNadia Khalil
Nadia Khalil
AKAliaa Moh Kamal
Aliaa Moh Kamal
SESoha Hussein Emam
Soha Hussein Emam
Various 1,3,4-oxadiazole-2-thiol derivatives have considerable potential in the field of antitumor activity. On the basis of the structure of the highly active reported oxadiazole analogues, 36 novel compounds were designed. Their molecular transport properties were predicted using a computer-aided program, and they were then synthesized and tested for anticancer activity against the breast cancer cell line MCF-7. Most of the tested compounds showed excellent to potent cytotoxic activity. Docking studies were carried out to examine the possibilities of the target compounds to become lead compounds in the future after more biological investigations. Compounds 18 and 22 were more active than the reference drug with IC₅₀ values of 0.010 µM and 0.012 µM, respectively, and binding energy scores of -10.32 and -10.25, respectively.